Client Login :: News :: Events :: Investor Relations :: Careers :: Publications :: Ordering
Home :: Site Map :: Contact Us
 
  • Patients
    • About MammaPrint
    • Questions & Answers
    • FDA Clearance
    • Getting Your MammaPrint
    • MammaPrint Providers
    • Insurance Coverage
      • Questions & Answers
    • Clinical Trials
      • MINDACT
      • MP-90
      • PARSC
    • Awards and Recognition
    • MammaPrint in Nederland
  • Physicians
    • MammaPrint
      • Unbiased Science
        • Gene Expression Profiling
        • Microarray Technology
        • RNA Integrity
        • 70 Genes Cover the Metastatic Cascade
        • Developed on Untreated Patients
      • Validation
      • Prognosis & Prediction
      • FDA Clearance
      • Patient Eligibility in the USA
      • Patient Eligibility Internationally
      • Publications & Abstracts
      • Test Results
        • Customer Pages
      • Ordering MammaPrint
        • Sampling Instructions
        • Order Kits
      • Insurance Coverage
      • Clinical Trials
    • TargetPrint
      • TargetPrint for ER/PR/HER2
        • Why Gene Expression
      • Validation
      • Results
      • Ordering
    • Research Gene Panel
    • DiscoverPrint
      • About DiscoverPrint
      • In Clinical Trials
      • Why Agendia
      • Ordering
    • ColoPrint
      • ColoPrint For Early Stage Colon Cancer Patients
      • ColoPrint Development and Validation
    • Ordering
      • Order Kits
      • Sampling Instructions
    • Customer Pages
    • Publications
    • Accreditation
    • Clinical Trials
      • MINDACT
        • MINDACT Coordination
        • MINDACT Locations
        • MINDACT Information
      • MP-90
      • PARSC
      • Locations
      • Contacts
    • Research
    • Insurance Coverage
      • FAQ's
      • Agendia Cares Commitment
  • About Us
    • Mission
    • History
    • Leadership
      • Executive Management
      • Supervisory Board
      • Medical & Scientific Advisory Board
    • Awards and Recognition
    • News
    • Events
    • Strategic Alliances
    • Investor Relations
    • Pipeline
    • Careers
      • Current Postings
    • Contact Us
 
  • MammaPrint
    • Unbiased Science
      • Gene Expression Profiling
      • Microarray Technology
      • RNA Integrity
      • 70 Genes Cover the Metastatic Cascade
      • Developed on Untreated Patients
    • Validation
    • Prognosis & Prediction
    • FDA Clearance
    • Patient Eligibility in the USA
    • Patient Eligibility Internationally
    • Publications & Abstracts
    • Test Results
      • Customer Pages
    • Ordering MammaPrint
      • Sampling Instructions
      • Order Kits
    • Insurance Coverage
    • Clinical Trials
  • TargetPrint
    • TargetPrint for ER/PR/HER2
      • Why Gene Expression
    • Validation
    • Results
    • Ordering
  • Research Gene Panel
  • DiscoverPrint
    • About DiscoverPrint
    • In Clinical Trials
    • Why Agendia
    • Ordering
  • ColoPrint
    • ColoPrint For Early Stage Colon Cancer Patients
    • ColoPrint Development and Validation
  • Ordering
    • Order Kits
    • Sampling Instructions
  • Customer Pages
  • Publications
  • Accreditation
  • Clinical Trials
    • MINDACT
      • MINDACT Coordination
      • MINDACT Locations
      • MINDACT Information
    • MP-90
    • PARSC
    • Locations
    • Contacts
  • Research
  • Insurance Coverage
    • FAQ's
    • Agendia Cares Commitment

ColoPrint® Development and Validation


ColoPrint is currently in the validation stage and scheduled to be launched in 2010.  Agendia is actively engaging academic centers and medical institutions throughout the USA and internationally to participate in the PARSC clinical trial.


For more information about participation in the PARSC trial, please visit the PARSC Clinical Trial for Colon Cancer page.

 

 


 
Patients :: Physicians :: About Us :: Login :: News :: Events :: Investor Relations :: Careers :: Publications :: Ordering :: Home :: Site Map :: Contact Us
© Agendia 2009 | Recommendation | Terms of use | Legal notices | Privacy Policy